Next Article in Journal
Effects of Background Music on Mental Fatigue in Steady-State Visually Evoked Potential-Based BCIs
Next Article in Special Issue
The Link between HRM Practices and Performance in Healthcare: The Mediating Role of the Organizational Change Process
Previous Article in Journal
Assessing the Predictive Power of Frailty and Life-Space Mobility on Patient-Reported Outcomes of Disability in Older Adults with Low Back Pain
Previous Article in Special Issue
Depression in Central and Eastern Europe: How Much It Costs? Cost of Depression in Romania
 
 
Article
Peer-Review Record

Vial Sharing of High-Cost Drugs to Decrease Leftovers and Costs: A Retrospective Observational Study on Patisiran Administration in Bologna, Italy

Healthcare 2023, 11(7), 1013; https://doi.org/10.3390/healthcare11071013
by Margherita Cozzio 1,2, Alessandro Melis 1,2, Giusy La Fauci 1,2,*, Pietro Guaraldi 3, Rosaria Caputo 4, Flavia Lioi 4,5, Giulia Sangiorgi Cellini 4, Giuseppina Santilli 4, Donatella Scarlattei 4, Pasquale Siravo 4, Paola Zuccheri 4, Andrea Ziglio 2,6 and Marco Montalti 1,2
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Healthcare 2023, 11(7), 1013; https://doi.org/10.3390/healthcare11071013
Submission received: 7 February 2023 / Revised: 31 March 2023 / Accepted: 31 March 2023 / Published: 2 April 2023
(This article belongs to the Special Issue Healthcare Management and Health Economics)

Round 1

Reviewer 1 Report

The total healthcare expenditure in Italy should be mentioned in the opening paragraph, I believe you will find this information in the Eurostat database.

None of the tables have a legend explaining symbols and abbreviations.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The authors provide a vial-sharing model for reducing discarded drug amounts for an orphan disease in the manuscript. 

The approach is reasonable, but the quality of the manuscript is concerning. 

-Please remove statistical details like the t-test from the abstract, and decipher abbreviations like KBW. Also, the names of the centers and timelines are not essential for the readers. The last sentence also should be removed from the abstract, so I recommend rewriting it. 

-Please also add a flow diagram of the study design

-Table 3 is hard to understand; please remake it or add it to the supplementary. Also, please improve table 3, so readers can make some conclusions, not just make an observation.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 3 Report

This study shows that the introduction of vial sharing in high-cost orphan drug use with patisiran leads to a significant reduction in discarded drug rate. Statistical analysis is quite fine, and finds a cost saving of 23,204 euros per year for a standard patient. The work has some limitations with phase 2 monitoring being of limited duration and the tertiary referral center being not a hub center (fewer users). Some mistakes in English should be corrected. For instance, "expensivedrug" and "wheight" (sic).

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop